Tulobuterol is a pharmacologically active or chemically reactive compound used in pharmaceutical manufacturing as an active ingredient, synthetic intermediate, or process reagent, requiring toxicological characterisation to establish protective occupational exposure limits. Available data from in vitro and in vivo studies are evaluated in a weight-of-evidence assessment to identify the critical study, the most sensitive adverse effect endpoint, and the applicable NOAEL or LOAEL that serves as the point of departure for PDE calculation. Data gaps are addressed through read-across from structurally related compounds, (Q)SAR predictions, or application of TTC defaults where scientifically justified.
The Acceptable Daily Exposure (ADE) for Tulobuterol is derived using methodology consistent with the ISPE Risk-Based Manufacture guide, providing an internally consistent health-based limit applicable across the complete pharmaceutical product lifecycle from API synthesis through to patient administration.